Scienture to commercially launch REZENOPY through Kindeva collaboration
HOLDINGS announce that its wholly owned subsidiary, Scienture has entered into a definitive agreement with SUMMIT BIOSCIENCES, ...
SCIENTURE to commercially launch REZENOPY®, a life-saving opioid overdose emergency treatment through a collaboration with KINDEVA DRUG DELIVERY L.P.
SCIENTURE HOLDINGS, INC. NASDAQ: SCNX), a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and caregivers through ...
What's Going On With Scienture Stock Thursday?
Scienture Holdings, Inc. SCNX stock is trading higher on Thursday after the company partnered with Kindeva to launch REZENOPY ...
Nasdaq9d
Scienture Holdings, Inc. Secures Exclusive U.S. Rights for REZENOPY® Naloxone Nasal Spray to Combat Opioid Overdose
The addition of REZENOPY to Scienture’s product portfolio aligns with Scienture’s mission to provide innovative treatment solutions across therapeutic areas and expand access to patients.
Mena FN9d
SCIENTURE To Commercially Launch REZENOPY®, A Life-Saving Opioid Overdose Emergency Treatment Through A Collaboration With KINDEVA DRUG DELIVERY L.P.
Under the terms of the collaboration, Kindeva will manufacture and commercially supply REZENOPY ® (naloxone HCl) Nasal Spray 10mg. Scienture will own the new drug application (NDA) for REZENOPY ...